Reassurance, not a green light, on GLP-1 exposure around conception

Design

Systematic review and random-effects meta-analysis of 22 cohort and observational studies

Population

49,395 pregnancies with periconceptional GLP-1 receptor agonist exposure vs unexposed

Primary outcome

Major congenital malformations and adverse obstetric and neonatal outcomes

Effect

No significant association across major outcomes; renal malformations odds ratio 1.23 (95% CI 1.09 to 1.39)

More reproductive-age women are taking glucagon-like peptide-1 (GLP-1) receptor agonists for weight and diabetes, so inadvertent exposure before a pregnancy is recognised is now a common counselling problem. This systematic review pooled 22 cohort and observational studies covering 49,395 pregnancies with periconceptional exposure.

Across major congenital and cardiac malformations, gestational age and weight, preterm birth, live birth, pregnancy loss, hypertensive disorders and caesarean, there was no statistically significant association with exposure. The single exception was a small association with renal malformations, odds ratio 1.23 (95% CI 1.09 to 1.39), which the authors attribute largely to one large cohort with substantial baseline imbalances.

For clinic, this supports calm counselling after an unplanned exposure rather than a change in practice. The drug should still be stopped once pregnancy is confirmed, and women planning pregnancy moved to an agent with a pregnancy record. Reassure, arrange the standard anomaly scan, and do not escalate to invasive testing on the basis of exposure alone.

• Reassure a woman with inadvertent first-trimester GLP-1 exposure that pooled human data show no consistent rise in major or cardiac malformations.
• Advise stopping the GLP-1 agonist once pregnancy is confirmed; the evidence supports reassurance, not continued use.
• Treat the lone renal-malformation signal (odds ratio 1.23) as likely reflecting maternal disease rather than the drug.
• For women trying to conceive, switch pre-pregnancy to an agent with an established pregnancy safety record.
• Offer the routine anomaly scan after exposure rather than extra invasive testing.

Why it matters

The question women on semaglutide or tirzepatide actually ask when a pregnancy is unplanned now has pooled human data behind the answer.

Don't overread it

These were observational studies offering reassurance after exposure; they do not license continuing a GLP-1 agonist during pregnancy.

The statistics, in plain English

The renal-malformation interval (1.09 to 1.39) excludes 1.0, so it is statistically significant, but it rests largely on one cohort with baseline imbalances, so confounding by maternal obesity and diabetes is the more likely explanation than a drug effect.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.